Table 4.
Age group | Variable | Study - country | ||||||
---|---|---|---|---|---|---|---|---|
Sm2 - Kenya | Sm2 - Tanzania | Sh2 – Mozambique | Sh2 – Niger | Sm1 - Côte d’Ivoire | Sm1 - Kenya | Sh1 - Niger | ||
5–8 years | Number enrolled | 4,725 | 12,359 | 7,463 | 13,553 | 4,812 | 1,609 | 6,667 |
Prevalence (%) | 35.7 | 38.5 | 63.1 | 24.0 | 5.3 | 5.8 | 3.3 | |
9–12 years | Number enrolled | 11,541 | 14,620 | 7,317 | 14,249 | 7,410 | 4,614 | 6,682 |
Prevalence (%) | 62.7 | 55.5 | 66.6 | 21.3 | 20.9 | 17.7 | 4.2 | |
Adults (20–55 years) | Number enrolled | 7,107 | 4,922 | 4,259 | 7,041 | N/A | N/A | N/A |
Prevalence (%) | 44.7 | 28.1 | 44.8 | 11.3 | N/A | N/A | N/A | |
Total | Number enrolled | 23,373 | 31,901 | 19,039 | 34,843 | 12,222 | 6,223 | 13,349 |
N/A not assessed, Sh1 sustaining control study in S. haematobium endemic villages, Sh2 gaining control study in S. haematobium endemic villages, Sm1 sustaining control study in S. mansoni endemic villages, Sm2 gaining control study in S. mansoni endemic villages